Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials
ABSTRACTTriple-negative breast cancer (TNBC) is the most aggressive breast cancer. Neoadjuvant chemotherapy was widely accepted for treating TNBC. This systematic review and meta-analysis aimed to evaluate the efficacy, safety, and survival benefit of platinum-based adjuvant therapy (PBAT) in treati...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-06-01
|
| Series: | Bioengineered |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21655979.2022.2115616 |
| _version_ | 1811175409761386496 |
|---|---|
| author | Kaigang Xie Xuanlei Ren Xiaoming Hong Shuiyin Zhu Dongjie Wang Xiaoming Ye Xiaoting Ren |
| author_facet | Kaigang Xie Xuanlei Ren Xiaoming Hong Shuiyin Zhu Dongjie Wang Xiaoming Ye Xiaoting Ren |
| author_sort | Kaigang Xie |
| collection | DOAJ |
| description | ABSTRACTTriple-negative breast cancer (TNBC) is the most aggressive breast cancer. Neoadjuvant chemotherapy was widely accepted for treating TNBC. This systematic review and meta-analysis aimed to evaluate the efficacy, safety, and survival benefit of platinum-based adjuvant therapy (PBAT) in treating TNBC. The keywords were searched in Medline, Embase, Pubmed, and Cochrane Library database up to July 24, 2022. All the randomized control trials (RCTs) comparing PBAT and non-PBAT in treating TNBC were included in our study. The pathological complete remission (pCR) and complications were compared by odds ratio (OR) and 95% confidence intervals (CIs). The overall survival (OS) and relapse-free survival (RFS) were compared by hazard ratio (HR) and 95% CIs. A total of 19 RCTs were included in our meta-analysis, among which 2,501 patients were treated with PBAT and 2,290 with non-PBAT. The patients treated with PBAT combined a significantly higher pCR rate compared to those patients treated with non-PBAT (49.8% versus 36.4%, OR = 1.27, 95%CI = 1.14–1.43, P < 0.001). Besides, patients treated with PBAT had a significantly better RFS (HR = 0.78, 95%CI = 0.63–0.95, P = 0.016), but not in OS (HR = 0.84, P = 0.304). Although the occurrence of neutropenia and nausea were slightly different between the PBAT group (51.5% and 24.4%) and the non-PBAT group (47.0% and 29.4%), the complications were acceptable in the two treatments groups. Our results demonstrated that TNBC patients treated with PBAT could achieve a higher pCR rate and better RFS benefit without a higher complication rate.Highlights Platinum-based adjuvant therapy provided a higher pCR rate for TNBC.Platinum-based adjuvant therapy prolonged the RFS but without prolongingthe OS.Neutropenia and nausea rate was different between group PBAT and non-PBAT. |
| first_indexed | 2024-04-10T19:36:45Z |
| format | Article |
| id | doaj.art-8e6453995e4c4b17864fdbc9884457d7 |
| institution | Directory Open Access Journal |
| issn | 2165-5979 2165-5987 |
| language | English |
| last_indexed | 2024-04-10T19:36:45Z |
| publishDate | 2022-06-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Bioengineered |
| spelling | doaj.art-8e6453995e4c4b17864fdbc9884457d72023-01-30T05:02:00ZengTaylor & Francis GroupBioengineered2165-59792165-59872022-06-01136148271483910.1080/21655979.2022.2115616Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trialsKaigang Xie0Xuanlei Ren1Xiaoming Hong2Shuiyin Zhu3Dongjie Wang4Xiaoming Ye5Xiaoting Ren6Department of General Surgery, the Yinzhou Second Hospital, Ningbo, ChinaDepartment of General Surgery, the Yinzhou Second Hospital, Ningbo, ChinaDepartment of General Surgery, the Yinzhou Second Hospital, Ningbo, ChinaDepartment of General Surgery, the Yinzhou Second Hospital, Ningbo, ChinaDepartment of General Surgery, the Yinzhou Second Hospital, Ningbo, ChinaDepartment of General Surgery, the Yinzhou Second Hospital, Ningbo, ChinaDepartment of General Surgery, the Yinzhou Second Hospital, Ningbo, ChinaABSTRACTTriple-negative breast cancer (TNBC) is the most aggressive breast cancer. Neoadjuvant chemotherapy was widely accepted for treating TNBC. This systematic review and meta-analysis aimed to evaluate the efficacy, safety, and survival benefit of platinum-based adjuvant therapy (PBAT) in treating TNBC. The keywords were searched in Medline, Embase, Pubmed, and Cochrane Library database up to July 24, 2022. All the randomized control trials (RCTs) comparing PBAT and non-PBAT in treating TNBC were included in our study. The pathological complete remission (pCR) and complications were compared by odds ratio (OR) and 95% confidence intervals (CIs). The overall survival (OS) and relapse-free survival (RFS) were compared by hazard ratio (HR) and 95% CIs. A total of 19 RCTs were included in our meta-analysis, among which 2,501 patients were treated with PBAT and 2,290 with non-PBAT. The patients treated with PBAT combined a significantly higher pCR rate compared to those patients treated with non-PBAT (49.8% versus 36.4%, OR = 1.27, 95%CI = 1.14–1.43, P < 0.001). Besides, patients treated with PBAT had a significantly better RFS (HR = 0.78, 95%CI = 0.63–0.95, P = 0.016), but not in OS (HR = 0.84, P = 0.304). Although the occurrence of neutropenia and nausea were slightly different between the PBAT group (51.5% and 24.4%) and the non-PBAT group (47.0% and 29.4%), the complications were acceptable in the two treatments groups. Our results demonstrated that TNBC patients treated with PBAT could achieve a higher pCR rate and better RFS benefit without a higher complication rate.Highlights Platinum-based adjuvant therapy provided a higher pCR rate for TNBC.Platinum-based adjuvant therapy prolonged the RFS but without prolongingthe OS.Neutropenia and nausea rate was different between group PBAT and non-PBAT.https://www.tandfonline.com/doi/10.1080/21655979.2022.2115616triple-negative breast cancerplatinumneoadjuvant therapysurvival |
| spellingShingle | Kaigang Xie Xuanlei Ren Xiaoming Hong Shuiyin Zhu Dongjie Wang Xiaoming Ye Xiaoting Ren Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials Bioengineered triple-negative breast cancer platinum neoadjuvant therapy survival |
| title | Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials |
| title_full | Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials |
| title_fullStr | Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials |
| title_full_unstemmed | Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials |
| title_short | Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials |
| title_sort | platinum based adjuvant therapy was efficient for triple negative breast cancer a meta analysis from randomized controlled trials |
| topic | triple-negative breast cancer platinum neoadjuvant therapy survival |
| url | https://www.tandfonline.com/doi/10.1080/21655979.2022.2115616 |
| work_keys_str_mv | AT kaigangxie platinumbasedadjuvanttherapywasefficientfortriplenegativebreastcancerametaanalysisfromrandomizedcontrolledtrials AT xuanleiren platinumbasedadjuvanttherapywasefficientfortriplenegativebreastcancerametaanalysisfromrandomizedcontrolledtrials AT xiaominghong platinumbasedadjuvanttherapywasefficientfortriplenegativebreastcancerametaanalysisfromrandomizedcontrolledtrials AT shuiyinzhu platinumbasedadjuvanttherapywasefficientfortriplenegativebreastcancerametaanalysisfromrandomizedcontrolledtrials AT dongjiewang platinumbasedadjuvanttherapywasefficientfortriplenegativebreastcancerametaanalysisfromrandomizedcontrolledtrials AT xiaomingye platinumbasedadjuvanttherapywasefficientfortriplenegativebreastcancerametaanalysisfromrandomizedcontrolledtrials AT xiaotingren platinumbasedadjuvanttherapywasefficientfortriplenegativebreastcancerametaanalysisfromrandomizedcontrolledtrials |